Calendario›SXTP›Tafenoquine
Tafenoquine
Expanded Use in Persistent (B. Microti) Babesiosis
Ensayo de 60 DEGREES PHARMACEUTICALS, INC. en Persistent Babesiosis (del registro, en inglés).
- Fase
- no aplica
- Estado
- Disponible por acceso ampliado
Qué significa cada fase y cada estado.
Estudio de acceso ampliado.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe purpose of this expanded access protocol is to offer a potentially effective treatment (tafenoquine) to patients with persistent babesiosis, who have not responded to standard of care treatments, and who are immunocompromised and thus at risk for more serious complications. Tafenoquine will be self-administered orally as 2 x 100 mg dark pink coated tablets once daily (total daily dose 200 mg) with food on Days 1, 2, 3 \& 4 then weekly thereafter (starting on day 11) until the patient has two consecutive negative PCR tests for Babesia parasites and symptoms of babesiosis have resolved. Other standard of care treatments recommended in the 2020 IDSA Guideline on Diagnosis and Management of Babesiosis should also be included in the treatment regimen.
Más ensayos de SXTP
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Tafenoquine 100mg · TQ-BA-2024-3 | Fase 2 | Reclutando pacientes | feb 2027 (prevista) |
| Tafenoquine | Fase 2 | Reclutando pacientes | mar 2027 (prevista) |
| Tafenoquine Oral Tablet | Fase 2 | Completado | jun 2022 (real) |
| Tafenoquine | Fase 2 | Completado | jul 2021 (real) |
Todos los de SXTP, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06478641), actualizada en nov 2025.